JP2015044875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015044875A5 JP2015044875A5 JP2014248337A JP2014248337A JP2015044875A5 JP 2015044875 A5 JP2015044875 A5 JP 2015044875A5 JP 2014248337 A JP2014248337 A JP 2014248337A JP 2014248337 A JP2014248337 A JP 2014248337A JP 2015044875 A5 JP2015044875 A5 JP 2015044875A5
- Authority
- JP
- Japan
- Prior art keywords
- antidiabetic agent
- pharmaceutical composition
- pharmaceutically acceptable
- group
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003472 antidiabetic agent Substances 0.000 claims description 65
- 229940125708 antidiabetic agent Drugs 0.000 claims description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 29
- 229940100389 Sulfonylurea Drugs 0.000 claims description 28
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 28
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 24
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 19
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 18
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 18
- 229960003105 metformin Drugs 0.000 claims description 18
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 16
- 210000000577 adipose tissue Anatomy 0.000 claims description 15
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 14
- 230000002641 glycemic effect Effects 0.000 claims description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 13
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 12
- 229940123208 Biguanide Drugs 0.000 claims description 12
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 12
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 229960005095 pioglitazone Drugs 0.000 claims description 12
- 206010022489 Insulin Resistance Diseases 0.000 claims description 10
- 150000004283 biguanides Chemical class 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 150000001467 thiazolidinediones Chemical class 0.000 claims description 9
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 8
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims description 8
- 230000003915 cell function Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229960001110 miglitol Drugs 0.000 claims description 8
- 229960000698 nateglinide Drugs 0.000 claims description 8
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 8
- 229960004586 rosiglitazone Drugs 0.000 claims description 8
- 229960001729 voglibose Drugs 0.000 claims description 8
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 7
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 7
- 229960002632 acarbose Drugs 0.000 claims description 7
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 7
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 230000006870 function Effects 0.000 claims description 7
- 229960002354 repaglinide Drugs 0.000 claims description 7
- 206010054805 Macroangiopathy Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 238000009097 single-agent therapy Methods 0.000 claims description 6
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 5
- 208000002177 Cataract Diseases 0.000 claims description 5
- 208000008960 Diabetic foot Diseases 0.000 claims description 5
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 5
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 5
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims description 5
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 5
- 208000017442 Retinal disease Diseases 0.000 claims description 5
- 206010038923 Retinopathy Diseases 0.000 claims description 5
- 208000007718 Stable Angina Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 238000009825 accumulation Methods 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- -1 glyquidone Chemical compound 0.000 claims description 5
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 5
- 201000008980 hyperinsulinism Diseases 0.000 claims description 5
- 230000003914 insulin secretion Effects 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 229960002397 linagliptin Drugs 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 201000001119 neuropathy Diseases 0.000 claims description 5
- 230000007823 neuropathy Effects 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 230000033764 rhythmic process Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 230000002792 vascular Effects 0.000 claims description 5
- 206010002388 Angina unstable Diseases 0.000 claims description 4
- 208000007814 Unstable Angina Diseases 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000002651 drug therapy Methods 0.000 claims description 4
- 229960004580 glibenclamide Drugs 0.000 claims description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000000291 postprandial effect Effects 0.000 claims description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000020358 Learning disease Diseases 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 230000008694 endothelial dysfunction Effects 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 201000003723 learning disability Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 2
- 108010011459 Exenatide Proteins 0.000 claims description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 2
- 108010019598 Liraglutide Proteins 0.000 claims description 2
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 claims description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960001519 exenatide Drugs 0.000 claims description 2
- 229960001764 glibornuride Drugs 0.000 claims description 2
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 claims description 2
- 229960000346 gliclazide Drugs 0.000 claims description 2
- 229960004346 glimepiride Drugs 0.000 claims description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 2
- 229960001381 glipizide Drugs 0.000 claims description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 2
- 229960002701 liraglutide Drugs 0.000 claims description 2
- 229960001093 lixisenatide Drugs 0.000 claims description 2
- 108010004367 lixisenatide Proteins 0.000 claims description 2
- 229940035736 metformin and pioglitazone Drugs 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 229960005371 tolbutamide Drugs 0.000 claims description 2
- 229960001641 troglitazone Drugs 0.000 claims description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 2
- 230000003178 anti-diabetic effect Effects 0.000 claims 5
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 206010001580 Albuminuria Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 229950009226 ciglitazone Drugs 0.000 claims 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 208000001145 Metabolic Syndrome Diseases 0.000 description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 5
- 208000004611 Abdominal Obesity Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 201000009104 prediabetes syndrome Diseases 0.000 description 3
- 206010065941 Central obesity Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- JSYGLDMGERSRPC-FQUUOJAGSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 JSYGLDMGERSRPC-FQUUOJAGSA-N 0.000 description 1
- GUYMHFIHHOEFOA-ZCPGHIKRSA-N Carmegliptin Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)C[C@@H](CF)CC1=O GUYMHFIHHOEFOA-ZCPGHIKRSA-N 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010056559 Graft infection Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229950003594 carmegliptin Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229950005754 gosogliptin Drugs 0.000 description 1
- QWEWGXUTRTXFRF-KBPBESRZSA-N gosogliptin Chemical compound C1C(F)(F)CCN1C(=O)[C@H]1NC[C@@H](N2CCN(CC2)C=2N=CC=CN=2)C1 QWEWGXUTRTXFRF-KBPBESRZSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229950009585 melogliptin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- 108010048573 taspoglutide Proteins 0.000 description 1
- 229950000034 teneligliptin Drugs 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09152869 | 2009-02-13 | ||
| EP09152869.5 | 2009-02-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549582A Division JP2012517977A (ja) | 2009-02-13 | 2010-02-12 | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017003403A Division JP6556767B2 (ja) | 2009-02-13 | 2017-01-12 | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015044875A JP2015044875A (ja) | 2015-03-12 |
| JP2015044875A5 true JP2015044875A5 (cg-RX-API-DMAC7.html) | 2015-10-08 |
Family
ID=42174359
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549582A Withdrawn JP2012517977A (ja) | 2009-02-13 | 2010-02-12 | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
| JP2014248337A Pending JP2015044875A (ja) | 2009-02-13 | 2014-12-08 | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
| JP2017003403A Active JP6556767B2 (ja) | 2009-02-13 | 2017-01-12 | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549582A Withdrawn JP2012517977A (ja) | 2009-02-13 | 2010-02-12 | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017003403A Active JP6556767B2 (ja) | 2009-02-13 | 2017-01-12 | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20120094894A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2395988A2 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2012517977A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20110115582A (cg-RX-API-DMAC7.html) |
| CN (3) | CN102387795A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010212823B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1013639A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2752437C (cg-RX-API-DMAC7.html) |
| CL (1) | CL2011001853A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA029759B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL213716A0 (cg-RX-API-DMAC7.html) |
| MX (2) | MX387264B (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ594044A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010092163A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| JP5323684B2 (ja) | 2006-05-04 | 2013-10-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 多形体 |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| EP2326326B1 (en) * | 2008-08-15 | 2019-10-09 | Boehringer Ingelheim International GmbH | Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients |
| JP2012502081A (ja) | 2008-09-10 | 2012-01-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連症状の治療のための組み合わせ治療 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| PL3228320T3 (pl) | 2008-10-17 | 2020-06-01 | Sanofi-Aventis Deutschland Gmbh | Kombinacja insuliny i agonisty GLP-1 |
| TWI508965B (zh) | 2008-12-23 | 2015-11-21 | Boehringer Ingelheim Int | 有機化合物的鹽形式 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| US20110046076A1 (en) | 2009-02-13 | 2011-02-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| DK2486029T3 (en) | 2009-09-30 | 2015-08-24 | Boehringer Ingelheim Int | Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives. |
| UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
| PT2498758T (pt) | 2009-11-13 | 2018-10-23 | Astrazeneca Uk Ltd | Formulações de comprimido bicamada |
| SI2498801T1 (en) | 2009-11-13 | 2018-06-29 | Sanofi-Aventis Deutschland Gmbh | A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine |
| CA3011480C (en) | 2009-11-13 | 2021-11-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| KR20190071840A (ko) | 2009-11-27 | 2019-06-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CN102883711A (zh) * | 2010-05-05 | 2013-01-16 | 贝林格尔.英格海姆国际有限公司 | 包含吡格列酮和利格列汀的药物组合物 |
| MX366325B (es) | 2010-05-05 | 2019-07-05 | Boehringer Ingelheim Int | Terapia de combinacion. |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| CA2803504C (en) | 2010-06-24 | 2022-08-30 | Boehringer Ingelheim International Gmbh | A combination for diabetes therapy comprising linagliptin and a long-acting insulin |
| EP2611458B1 (en) | 2010-08-30 | 2016-09-21 | Sanofi-Aventis Deutschland GmbH | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| KR102117282B1 (ko) * | 2010-11-15 | 2020-06-01 | 베링거 인겔하임 인터내셔날 게엠베하 | 혈관보호성 및 심장보호성 항당뇨 치료요법 |
| AU2016202261B2 (en) * | 2010-11-15 | 2017-11-30 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| HUE036066T2 (hu) * | 2010-12-16 | 2018-06-28 | Novo Nordisk As | GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények |
| EP2468268B1 (en) * | 2010-12-21 | 2017-12-13 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Combination composition of vildagliptin and gliclazide |
| TR201101809A1 (tr) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Vildagliptin ve glimepirid kombinasyonları. |
| TR201107482A1 (tr) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu. |
| TW201236692A (en) * | 2011-02-02 | 2012-09-16 | Sanofi Aventis Deutschland | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
| EP2679270B1 (en) * | 2011-02-24 | 2016-11-09 | Hisamitsu Pharmaceutical Co., Inc. | Glp-1 analogue composition for microneedle devices |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| EP3225631B1 (en) | 2011-04-12 | 2019-01-09 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| ES2556466T3 (es) * | 2011-05-13 | 2016-01-18 | Sanofi-Aventis Deutschland Gmbh | Lixisenatida y metformina para el tratamiento de la diabetes tipo 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| KR101985384B1 (ko) | 2011-07-15 | 2019-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도 |
| EP2750699B1 (en) | 2011-08-29 | 2015-07-22 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| US20130172244A1 (en) * | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9233102B2 (en) | 2012-03-07 | 2016-01-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| JP6356660B2 (ja) * | 2012-03-22 | 2018-07-11 | ノヴォ ノルディスク アー／エス | 送達剤を含む組成物およびその調製 |
| DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
| HRP20181447T1 (hr) | 2012-03-22 | 2018-11-02 | Novo Nordisk A/S | Pripravci glp-1 peptida i njihova priprava |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2013189988A1 (en) * | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| PL3689365T3 (pl) * | 2012-07-01 | 2025-11-12 | Novo Nordisk A/S | Zastosowanie peptydów glp-1 o przedłużonym działaniu |
| EP2882424B1 (en) * | 2012-08-13 | 2017-12-13 | Sandoz AG | Stable pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof |
| CN103877054B (zh) * | 2012-12-21 | 2016-05-25 | 北大方正集团有限公司 | 一种苯甲酸阿格列汀片剂及其制备方法 |
| WO2014102715A1 (en) | 2012-12-24 | 2014-07-03 | Ranbaxy Laboratories Limited | Pharmaceutical compositions comprising a biguanide and a low dose antidiabetic agent |
| EP4613284A3 (en) | 2013-04-03 | 2025-11-19 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| TR201901110T4 (tr) | 2013-04-05 | 2019-02-21 | Boehringer Ingelheim Int | Empagliflozinin terapötik kullanımları. |
| DK2986304T3 (da) | 2013-04-18 | 2022-04-04 | Boehringer Ingelheim Int | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf. |
| MY172578A (en) | 2013-05-02 | 2019-12-03 | Novo Nordisk As | Oral dosing of glp-1 compounds |
| WO2014184742A1 (en) | 2013-05-13 | 2014-11-20 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent |
| JP2016518438A (ja) * | 2013-05-17 | 2016-06-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＤＰＰ−４阻害薬とα−グルコシダーゼ阻害薬との組合せ |
| KR101598612B1 (ko) * | 2013-08-29 | 2016-02-26 | 재단법인 아산사회복지재단 | Dpp-4 억제제를 포함하는 혈관 또는 심장판막 석회화의 예방 또는 치료용 조성물 |
| EP2848242A1 (en) * | 2013-09-12 | 2015-03-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally disintegrating formulations of Linagliptin |
| EP2848241A1 (en) * | 2013-09-12 | 2015-03-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Effervescent formulations of linagliptin |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| EP3177292B1 (en) | 2014-08-07 | 2020-11-25 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| KR20160062517A (ko) * | 2014-11-25 | 2016-06-02 | 경북대학교병원 | Ｄｐｐ４ 저해제를 유효성분으로 함유하는 혈관 석회화 억제용 약학적 조성물 |
| PE20171622A1 (es) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | Formulacion de relacion fija de insulina glargina/lixisenatida |
| KR101526825B1 (ko) * | 2014-12-23 | 2015-06-08 | 주식회사 한독 | 당뇨병 치료용 약제학적 조성물 |
| AU2015384339B2 (en) * | 2015-02-27 | 2018-08-09 | The Asan Foundation | Composition for preventing or treating valve calcification, containing DPP-4 inhibitor |
| CN107530379A (zh) * | 2015-03-11 | 2018-01-02 | 佩特尼资源有限公司 | 用于治疗肥胖症和2型糖尿病(t2d)的胰腺内分泌祖细胞疗法 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| ES2791301T3 (es) * | 2015-11-06 | 2020-11-03 | Genesis Pharma Sa | Combinación de canrenoato y exenatida |
| KR101782119B1 (ko) * | 2016-02-01 | 2017-10-23 | 주식회사 한독 | 테넬리글립틴 및 설포닐우레아계 약물을 포함하는 정제 |
| BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
| KR102758804B1 (ko) | 2016-10-31 | 2025-01-23 | 엘지디스플레이 주식회사 | 발광 영역들을 포함하는 디스플레이 장치 |
| AU2017357589B2 (en) | 2016-11-10 | 2023-05-11 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| TWI700091B (zh) * | 2016-12-16 | 2020-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 含胰島素醫藥組成物 |
| MX2018006006A (es) * | 2017-02-03 | 2019-05-16 | Glenmark Pharmaceuticals Ltd | Sales de oxalato de teneligliptin y solvatos de este, intermediarios, proceso de preparacion y marcadores de estos. |
| KR102469957B1 (ko) * | 2017-06-30 | 2022-11-24 | 한미약품 주식회사 | 리나글립틴, 메트포르민 및 항산화제를 포함하는, 안정성이 개선된 약제학적 조성물 |
| KR20200069316A (ko) | 2017-10-12 | 2020-06-16 | 노보 노르디스크 에이/에스 | 의료 요법에서의 세마글루타이드 |
| KR102500835B1 (ko) * | 2017-10-24 | 2023-02-17 | 한미약품 주식회사 | 리나글립틴 및 메트포르민을 포함하는 복합제제 및 그의 제조방법 |
| WO2019147650A1 (en) | 2018-01-23 | 2019-08-01 | Gila Therapeutics, Inc. | Peptide yy pharmaceutical formulations, compositions, and methods |
| RS64643B1 (sr) | 2018-02-02 | 2023-10-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline i lubrikant |
| EP3811939A4 (en) * | 2018-05-31 | 2022-05-25 | Hua Medicine (Shanghai) Ltd. | PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING A GLUCOSIDASE ACTIVATOR AND A &X3B1;-GLUCOSIDASE INHIBITOR, METHODS OF PREPARING THEM AND USES THEREOF |
| MX2021000555A (es) * | 2018-07-17 | 2021-03-29 | Boehringer Ingelheim Int | Tratamiento antidiabetico cardiovascular seguro. |
| JP7684902B2 (ja) * | 2018-10-04 | 2025-05-28 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン及びこれを含む組合せ物の治療学的用途 |
| TW202102208A (zh) * | 2019-03-25 | 2021-01-16 | 澳大利亞喬治全球健康研究所 | 低劑量三重組合調配物 |
| US20220265776A1 (en) * | 2019-07-09 | 2022-08-25 | Genesis Pharma Sa | Combination |
| CN110314233B (zh) * | 2019-08-12 | 2021-07-23 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和dpp-4抑制剂的组合产品 |
| CN110652498B (zh) * | 2019-11-22 | 2022-04-05 | 河南合智医药科技有限公司 | 一种用于治疗2型糖尿病的药物制剂及其制备方法 |
| CN114641277B (zh) * | 2019-12-31 | 2023-06-13 | 石药集团中奇制药技术（石家庄）有限公司 | 一种二肽基肽酶4抑制剂的药物组合物及其制备方法和应用 |
| KR102289381B1 (ko) * | 2020-03-17 | 2021-08-17 | 주식회사 대웅테라퓨틱스 | 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| EP4415720A4 (en) * | 2021-10-17 | 2025-07-30 | Zenvision Pharma Llp | NEW PARENTERAL COMPOSITION COMPRISING LINAGLIPTIN OR ITS SALTS |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| TW225528B (cg-RX-API-DMAC7.html) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| PT1308439E (pt) | 2000-08-10 | 2008-12-12 | Mitsubishi Tanabe Pharma Corp | Derivados de prolina e sua utilização como fármacos |
| DK1757606T3 (da) | 2001-02-24 | 2009-09-07 | Boehringer Ingelheim Pharma | Anvendelse af xanthinderivater som l gemidler samt fremgangsm de til deres fremstilling |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| ATE453644T1 (de) | 2002-08-21 | 2010-01-15 | Boehringer Ingelheim Pharma | 8-[3-amino-piperidin-1-yl] -xanthine, deren herstellung und deren verwendung als arzneimittel |
| DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10254304A1 (de) | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| UY28103A1 (es) | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| DE10327439A1 (de) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| EA009591B1 (ru) | 2003-06-20 | 2008-02-28 | Ф.Хоффманн-Ля Рош Аг | Производные пиридо[2,1-а]изохинолина в качестве ингибиторов dpp-iv |
| JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| NZ547752A (en) | 2003-11-12 | 2009-12-24 | Phenomix Corp | Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV |
| DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10359098A1 (de) | 2003-12-17 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10360835A1 (de) | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
| ES2899417T3 (es) | 2004-01-20 | 2022-03-11 | Novartis Ag | Formulación y proceso de compresión directa |
| PL1712547T3 (pl) | 2004-02-05 | 2012-04-30 | Kyorin Seiyaku Kk | Pochodna bicykloestrowa |
| ATE430150T1 (de) | 2004-02-18 | 2009-05-15 | Boehringer Ingelheim Int | 8-ä3-amino-piperidin-1-ylü-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer |
| DE102004009039A1 (de) | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
| CN102134230B (zh) | 2004-03-15 | 2019-06-28 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| EP1740589A1 (de) | 2004-04-10 | 2007-01-10 | Boehringer Ingelheim International GmbH | Neue 2-amino-imidazo[4,5-d]pyridazin-4-one und 2-amino-imidazo[4,5-c]pyridin-4-one, deren herstellung und deren verwendung als arzneimittel |
| US7741082B2 (en) | 2004-04-14 | 2010-06-22 | Bristol-Myers Squibb Company | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor |
| PL1753748T3 (pl) | 2004-05-12 | 2010-01-29 | Pfizer Prod Inc | Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV |
| US7214702B2 (en) | 2004-05-25 | 2007-05-08 | Bristol-Myers Squibb Company | Process for producing a dipeptidyl peptidase IV inhibitor |
| TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| DE102004043944A1 (de) | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004044221A1 (de) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1802308A1 (en) | 2004-10-08 | 2007-07-04 | Novartis AG | Combination of organic compounds |
| AU2005293266B2 (en) | 2004-10-12 | 2011-09-29 | Glenmark Pharmaceuticals S.A. | Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation |
| KR20070068407A (ko) * | 2004-10-25 | 2007-06-29 | 노파르티스 아게 | Ｄｐｐ―ｉｖ 억제제, ｐｐａｒ 항당뇨병제 및메트포르민의 조합물 |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| BRPI0518651A2 (pt) | 2004-12-24 | 2008-12-02 | Dainippon Sumitomo Pharma | composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes |
| GT200600008A (es) | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
| TWI403511B (zh) | 2005-02-18 | 2013-08-01 | Mitsubishi Tanabe Pharma Corp | 脯胺酸衍生物之鹽、或其溶媒合物，以及其製造方法 |
| JP5043825B2 (ja) | 2005-03-22 | 2012-10-10 | エフ．ホフマン−ラ ロシュ アーゲー | Ｄｐｐ−ｉｖ阻害剤の新規な塩及び多形 |
| BRPI0608469A2 (pt) | 2005-04-22 | 2010-01-05 | Alantos Pharmaceuticals Holding Inc | inibidores de dipeptidil peptidase-iv |
| MX2007013301A (es) | 2005-04-26 | 2008-03-07 | Mitsubishi Tanabe Pharma Corp | Agente profilactico/terapeutico para la anormalidades del metabolismo del azucar/lipidos. |
| EP1894567B1 (en) | 2005-06-03 | 2012-08-15 | Mitsubishi Tanabe Pharma Corporation | Concomitant pharmaceutical agents and use thereof |
| MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| EP1901741B1 (en) | 2005-07-01 | 2015-09-16 | Merck Sharp & Dohme Corp. | Process for synthesizing a cetp inhibitor |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| BRPI0614610A2 (pt) | 2005-08-04 | 2011-04-05 | Novartis Ag | compostos |
| KR20080030652A (ko) | 2005-08-11 | 2008-04-04 | 에프. 호프만-라 로슈 아게 | Ｄｐｐ-ｉｖ 억제제를 포함하는 약학 조성물 |
| GEP20135791B (en) | 2005-09-14 | 2013-03-25 | Takeda Pharmaceutical | Use of dipeptidyl peptidase inhibitors |
| ATE532518T1 (de) | 2005-09-14 | 2011-11-15 | Takeda Pharmaceutical | Dipeptidyl-peptidase-hemmer zur behandlung von diabetes |
| CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| TW200745079A (en) | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
| WO2007050485A2 (en) | 2005-10-25 | 2007-05-03 | Merck & Co., Inc. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
| CN101341148A (zh) | 2005-12-21 | 2009-01-07 | 霍夫曼-拉罗奇有限公司 | 新型的dpp-iv抑制剂的盐和多晶型物 |
| AU2006327069A1 (en) | 2005-12-23 | 2007-06-28 | Novartis Ag | Condensed heterocyclic compounds useful as DPP-IV inhibitors |
| JP5094416B2 (ja) | 2005-12-28 | 2012-12-12 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| BRPI0706423A2 (pt) * | 2006-01-06 | 2011-03-29 | Novartis Ag | uso de compostos orgánicos |
| WO2007112368A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) * | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| JP5323684B2 (ja) | 2006-05-04 | 2013-10-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 多形体 |
| KR20070111099A (ko) * | 2006-05-16 | 2007-11-21 | 영진약품공업주식회사 | 시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물 |
| WO2007149797A2 (en) * | 2006-06-19 | 2007-12-27 | Novartis Ag | Use of organic compounds |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| WO2008001195A2 (en) | 2006-06-27 | 2008-01-03 | Glenmark Pharmaceuticals S.A. | Novel processes for the preparation of dpp iv inhibitors |
| JP2010500326A (ja) | 2006-08-08 | 2010-01-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の治療のためのｄｐｐ−ｉｖ阻害剤としてのピロロ［３，２−ｄ］ピリミジン |
| CL2007002499A1 (es) | 2006-08-30 | 2008-03-14 | Phenomix Corp | Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes. |
| SI2073810T1 (sl) | 2006-09-13 | 2011-12-30 | Takeda Pharmaceutical | Uporaba 2-6(3-amino-piperidin-1-il)-3-metil-2,4-diokso-3,4-dihidro-2H-pirimidin -1-ilmetil-4-fluoro-benzonitrila za zdravljenje diabetesa, raka, avtoimunskih motenj in infekcije s HIV |
| ATE522529T1 (de) | 2006-09-15 | 2011-09-15 | Hoffmann La Roche | Verfahren zur herstellung von pyridoä2,1- aüisochinolinderivaten, das die racematspaltung eines enamins umfasst |
| CN101511830B (zh) | 2006-09-15 | 2013-07-24 | 霍夫曼-拉罗奇有限公司 | 通过烯胺的催化不对称氢化制备吡啶并[2,1-a]异喹啉衍生物的方法 |
| US7956201B2 (en) | 2006-11-06 | 2011-06-07 | Hoffman-La Roche Inc. | Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| KR101486091B1 (ko) | 2007-02-01 | 2015-01-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 알로그립틴 및 피오글리타존을 포함하는 고형 제제 |
| CA2677193C (en) * | 2007-02-01 | 2015-06-30 | Takeda Pharmaceutical Company Limited | Tablet preparation without causing a tableting trouble |
| CN101679238A (zh) | 2007-03-08 | 2010-03-24 | 芬诺密克斯公司 | 用于合成选择性dpp-iv抑制剂的方法和中间体 |
| EP2120885A2 (en) | 2007-03-13 | 2009-11-25 | Takeda Pharmaceutical Company Limited | Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| JPWO2008114857A1 (ja) | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
| PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
| US20100247642A1 (en) | 2007-05-21 | 2010-09-30 | Phenomix Corporation | Stable pharmaceutical formulation for a dpp-iv inhibitor |
| EP2175727A4 (en) | 2007-07-12 | 2011-05-25 | Phenomix Corp | CRYSTALLINE SYNTHETIC INTERMEDIATE PRODUCT FOR PREPARING A DPP-IV HEMMER AND METHOD FOR CLEANING THE SAME |
| MY159203A (en) | 2007-07-19 | 2016-12-30 | Takeda Pharmaceuticals Co | Solid preparation comprising alogliptin and metformin hydrochloride |
| TW200938200A (en) | 2007-12-28 | 2009-09-16 | Dainippon Sumitomo Pharma Co | Methyl-substituted piperidine derivative |
| CN101234105A (zh) * | 2008-01-09 | 2008-08-06 | 北京润德康医药技术有限公司 | 一种含有二甲双胍和维格列汀的药用组合物及其制备方法 |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) * | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| UY32177A (es) * | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético |
| US20110046076A1 (en) * | 2009-02-13 | 2011-02-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| UY32427A (es) * | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
-
2010
- 2010-02-12 NZ NZ59404410A patent/NZ594044A/en unknown
- 2010-02-12 AU AU2010212823A patent/AU2010212823B2/en active Active
- 2010-02-12 BR BRPI1013639A patent/BRPI1013639A2/pt not_active Application Discontinuation
- 2010-02-12 CN CN2010800161446A patent/CN102387795A/zh active Pending
- 2010-02-12 MX MX2016013286A patent/MX387264B/es unknown
- 2010-02-12 CN CN201610580276.0A patent/CN106177958A/zh active Pending
- 2010-02-12 JP JP2011549582A patent/JP2012517977A/ja not_active Withdrawn
- 2010-02-12 CN CN202310997781.5A patent/CN117547538A/zh active Pending
- 2010-02-12 CA CA2752437A patent/CA2752437C/en active Active
- 2010-02-12 MX MX2011008416A patent/MX2011008416A/es unknown
- 2010-02-12 EP EP10704924A patent/EP2395988A2/en active Pending
- 2010-02-12 NZ NZ619520A patent/NZ619520A/en unknown
- 2010-02-12 KR KR1020117018784A patent/KR20110115582A/ko not_active Ceased
- 2010-02-12 KR KR1020167034411A patent/KR20160143897A/ko not_active Ceased
- 2010-02-12 EA EA201101187A patent/EA029759B1/ru not_active IP Right Cessation
- 2010-02-12 US US13/148,065 patent/US20120094894A1/en not_active Abandoned
- 2010-02-12 WO PCT/EP2010/051817 patent/WO2010092163A2/en not_active Ceased
-
2011
- 2011-06-22 IL IL213716A patent/IL213716A0/en unknown
- 2011-08-02 CL CL2011001853A patent/CL2011001853A1/es unknown
-
2014
- 2014-12-08 JP JP2014248337A patent/JP2015044875A/ja active Pending
- 2014-12-22 US US14/578,552 patent/US20150105318A1/en not_active Abandoned
-
2017
- 2017-01-12 JP JP2017003403A patent/JP6556767B2/ja active Active
- 2017-02-28 US US15/444,362 patent/US20170173027A1/en not_active Abandoned
-
2018
- 2018-08-09 US US16/059,413 patent/US20180344741A1/en not_active Abandoned
-
2020
- 2020-06-26 US US16/912,764 patent/US20200323861A1/en not_active Abandoned
-
2021
- 2021-12-03 US US17/541,357 patent/US20220088023A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015044875A5 (cg-RX-API-DMAC7.html) | ||
| AU2010237748B2 (en) | Pharmaceutical compositions | |
| AU2012328388B2 (en) | Treatment protocol of diabetes type 2 | |
| HRP20200828T1 (hr) | Farmaceutski pripravak koji sadrži sglt2-inhibitor, dpp-iv-inhibitor i prema potrebi jedno dodatno antidijabetičko sredstvo, te njegove uporabe | |
| JP2013540801A (ja) | 代謝異常の治療のための組合せ医薬 | |
| JP7266327B2 (ja) | 高血糖症を処置する方法 | |
| JP2015516404A (ja) | 代謝疾患の処置のための合剤 | |
| CN103402506A (zh) | 用于治疗糖尿病的组合 | |
| TWI519297B (zh) | 使用雙醋瑞因之糖尿病輔助療法 | |
| AU2014221222B2 (en) | Pharmaceutical compositions | |
| Chawla et al. | 42 A Right Combination a Day | |
| RU2021130019A (ru) | Состав низкодозовой тройной комбинации | |
| CN115192625A (zh) | 一种口服组合物 | |
| JP2011105609A (ja) | メトホルミンへの付加療法を含む２型糖尿病の治療方法 | |
| AU2016202866A1 (en) | Pharmaceutical compositions | |
| Fonseca | Pharmacological treatment of type 2 diabetes | |
| HK1165292A (en) | Pharmaceutical compositions |